# Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

> **NCT06658925** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
- HSCT
- Tyrosine Kinase Inhibitor

## Interventions

- **DRUG:** Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.

## Key facts

- **NCT ID:** NCT06658925
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06658925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06658925, "Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06658925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*